Thiomab-sirna
WebDelivery of siRNA is a key hurdle to realizing the therapeutic promise of RNAi. By targeting internalizing cell surface antigens, antibody-siRNA complexes provide a possible solution. …
Thiomab-sirna
Did you know?
WebPurification yields preparations that are free of uncoupled antibodies (mass at 147875) and contain conjugates with either one siRNA (ARC mass at 154451.2) or two siRNAs (ARC … WebMar 15, 2024 · Cuellar, T. L. et al. Systematic evaluation of antibody-mediated SiRNA delivery using an industrial platform of THIOMAB-SiRNA conjugates. Nucleic Acids Res. 43(2), 1189–1203.
WebOne of the most advanced approaches is the THIOMAB® technology, 46 which involves mutating amino acid residues at particular sites in the constant domains of the antibody to Cys ... with Alnylam Pharmaceuticals, they have generated a h38C2–siRNA (1: 2) conjugate via the β-lactam-based linker. 89 The conjugate successfully targeted human β ... WebMay 1, 2007 · A number of ThioMab-ADCs were produced and tested in both efficacy and toxicity models. The efficacy of the ThioMab-ADCs is equal if not superior to ADCs produced by the conventional method. Surprisingly, the safety of these conjugates is considerably better than that observed with the conventional ADCs. Therefore, ThioMab technology …
WebDec 30, 2014 · To assess and improve this delivery method, we built on an industrial platform of therapeutic antibodies called THIOMABs, engineered to enable precise … WebThe most recent reports in the antibody-siRNA-conjugates (ARCs) field add new dimensions to leukemic therapy, where a covalently ligated therapeutic antisense-RNA with the potential to repress the oncogenic transcript is selectively delivered into the cancer cells. Despite ARC localization to leukemic cells due to high affinity antigen-antibody ...
WebAntibodies bearing engineered cysteine residues (termed THIOMAB™ antibodies) enable the site-selective attachment of a drug, label or other payload for specific delivery to …
WebAntibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin. Cancer Res. 2015; 21: 1383-1394. ... Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res. 2015; 43: 1189-1203. foreign key other nameWebNational Center for Biotechnology Information did the ottomans conquer constantinopleWebDec 30, 2014 · THIOMAB–siRNA conjugates T rinna L. Cuellar 1, † , Dwight Barnes 2, † , Christopher Nelson 3 , Joshua T anguay 2 , Shang-Fan Y u 2 , Xiaohui W en 1 , Suzie J. … foreign key references in sqlWebJan 8, 2024 · This study utilized several sophisticated methods, including the application of site-specific engineered cysteine conjugation (Genentech’s THIOMAB™ platform) to deliver reproducible and largely homogeneous conjugates, as well as highly modified chemically-stabilized housekeeping gene (PPIB) siRNA constructs to enable in vivo studies. did the ottoman empire fall in ww1WebOne of the most advanced approaches is the THIOMAB® technology, 46 which involves mutating amino acid residues at particular sites in the constant domains of the antibody … foreign key references multiple primary keysWebDec 30, 2014 · ARCs were generated in two primary steps: the amine-tagged siRNA was reacted with a NHS-linker to form a thiol-reactive siRNA-linker adduct, and this adduct was then reacted with thiol groups on the THIOMAB to covalently link the siRNA via a thio-ester bond (Figure (Figure1a). 1a). ARCs were purified using anion exchange chromatography … foreign key reference target does not existWebSystematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates TL Cuellar, D Barnes, C Nelson, J Tanguay, SF Yu, X Wen, SJ Scales, ... Nucleic acids research 43 (2), 1189-1203 , 2015 foreign key references primary key